Nkarta, Inc.
News
We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely
Simply Wall St There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Nkarta ( NASDAQ:NKTX...\n more…
Nkarta to Participate in Upcoming Investor Conference
Globe Newswire SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced...\n more…
Nkarta (NASDAQ:NKTX) Rating Reiterated by Needham & Company LLC
Ticker Report Needham Company LLC reissued their buy rating on shares of Nkarta (NASDAQ:NKTX - Free Report) in a research note released on Wednesday, Benzinga reports. They currently have a $13.00 target...\n more…
Nkarta (NASDAQ:NKTX) PT Lowered to $22.00
Ticker Report Nkarta (NASDAQ:NKTX - Get Free Report) had its price objective dropped by stock analysts at HC Wainwright from $23.00 to $22.00 in a report released on Thursday, Benzinga reports. The brokerage...\n more…
HC Wainwright Brokers Increase Earnings Estimates for Nkarta, Inc. (NASDAQ:NKTX)
Ticker Report Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Analysts at HC Wainwright raised their Q3 2024 EPS estimates for shares of Nkarta in a research note issued to investors on Wednesday, August 14th. HC...\n more…
Q3 2024 Earnings Forecast for Nkarta, Inc. (NASDAQ:NKTX) Issued By William Blair
Ticker Report Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Equities researchers at William Blair lifted their Q3 2024 EPS estimates for Nkarta in a note issued to investors on Wednesday, August 14th. William Blair...\n more…